Oragenics Files 8-K on Jan 2, 2024; Confirms NYSE American Listing
Ticker: OGEN · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1174940
| Field | Detail |
|---|---|
| Company | Oragenics INC (OGEN) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, compliance, corporate-governance
TL;DR
**Oragenics filed a routine 8-K, no major news, just administrative updates.**
AI Summary
Oragenics, Inc. filed an 8-K on January 2, 2024, to report an "Other Event" and provide information on "Financial Statements and Exhibits." This filing primarily serves to update administrative details and confirm its status as a publicly traded company on the NYSE American under the ticker OGEN. For investors, this filing is largely procedural, indicating no immediate material changes to the company's operations or financial health, but it confirms their continued compliance with SEC reporting requirements.
Why It Matters
This filing is a routine administrative update, confirming Oragenics' continued compliance with SEC regulations and its listing on the NYSE American, which is important for maintaining investor confidence and market access.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not disclose any new financial risks or operational changes.
Analyst Insight
A smart investor would recognize this as a standard compliance filing with no immediate impact on investment decisions, but would continue to monitor for more substantive news or financial disclosures.
Key Players & Entities
- Oragenics, Inc. (company) — the registrant filing the 8-K
- NYSE American (company) — the exchange where Oragenics' Common Stock is registered
- OGEN (company) — the trading symbol for Oragenics' Common Stock
- January 2, 2024 (date) — the date of the earliest event reported and filing date
FAQ
What is the purpose of this specific 8-K filing by Oragenics, Inc.?
This 8-K filing by Oragenics, Inc. on January 2, 2024, reports an "Other Event" and provides information on "Financial Statements and Exhibits," primarily serving as a routine administrative update to confirm its status and compliance.
On what stock exchange is Oragenics, Inc.'s Common Stock traded, according to this filing?
According to the filing, Oragenics, Inc.'s Common Stock is registered on the NYSE American.
What is the trading symbol for Oragenics, Inc.?
The trading symbol for Oragenics, Inc.'s Common Stock is OGEN, as stated in the filing.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 2, 2024.
What is Oragenics, Inc.'s business address as listed in the filing?
Oragenics, Inc.'s business address is 4902 Eisenhower Boulevard, Suite 125, Tampa, FL 33634, according to the filing.
Filing Stats: 414 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-01-02 09:22:57
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 22KB
- 0001493152-24-000041.txt ( ) — 236KB
- ogen-20240102.xsd (EX-101.SCH) — 3KB
- ogen-20240102_lab.xml (EX-101.LAB) — 33KB
- ogen-20240102_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 2 nd day of January, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer